Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information


Currently viewing:

Administrative data

Description of key information

DMP did neither initiate nor promote cancer in a 1-year study in male CD-1 mice (NTP, 1993). 

Key value for chemical safety assessment

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
2 700 mg/kg bw/day
Study duration:

Justification for classification or non-classification

GHS classification (GHS UN rev.2, 2007): no classification required

Additional information

DMP-Carcinogenicityin vivo, Initiation/promotion study

DMP was tested in male CD-1 mice [NTP, 1993] for one year with one dose of 0.1 ml (calculated 2700 mg/kg bw; density=1.194g/ml). Neat substance was applied dermally on clipped skin over one year. In parallel DMBA (7,12-dimethylbenz(a)anthracene) and TPA (12-O-tetradecanoylphorbol-13-acetat) were used as positive controls for initiation and promotion, respectively. Combined treatment of DMBA and TPA lead to an increase of both squamous cell papillomas and squamous cell carcinomas. All TPA-dosed groups had significantly greater incidences of dermal acanthosis, ulceration, exudation, and hyperkeratosis than controls. Therefore the TPA exposure concentration was adjusted to 0.025 mg/ml (2x per week) from week 10 on (starting concentration: 0.05 mg/ml 3x per week).DMP treatment had no effect on body weight compared to vehicle controls.Incidences of neoplasms in the DMP treated mice (initiation) were similar to vehicle controls. Thus, DMP was not able to initiate skin carcinogenesis when chronically promoted by TPA. Furthermore, DMP did not promote skin carcinogenesis in skin initiated with DMBA. The test substance is not carcinogenic, nor does it initiate and/or promote cancer.